Major pharmaceutical manufacturer Pfizer is ending development of its twice-daily weight loss pill, danuglipron, the company announced Friday.
According to Pfizer, danuglipron users experienced major adverse side effects during the drug’s midstage clinical trial.
This marks Pfizer’s second scrapped weight loss drug project as the manufacturer aims to replicate the success of blockbuster weight loss drugs Wegovy and Ozempic.
Pfizer is expected to release data on its single-dose weight loss pill next month.
